Navigation Links
Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide
Date:4/9/2008

Multi-National Study Will Follow 60,000 Women for 5 Years

ISTANBUL, Turkey, April 10 /PRNewswire/ -- Nearly 60,000 women aged 55 years and older have enrolled in a landmark, multi-national study that will focus on the management of osteoporosis across the globe. Launch of the Global Longitudinal Registry of Osteoporosis in Women (GLOW) was announced today at ECCEO 8 (Eighth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) in Istanbul, Turkey. This groundbreaking observational study (registry) in osteoporosis aims to gain insights to improve the standard of care for postmenopausal women at risk of osteoporosis.

"We know that there are patients at high risk for osteoporosis, sometimes already having suffered a broken bone, who aren't getting diagnosed and treated. We have to figure out why not," said Dr. Robert Lindsay, GLOW Executive Committee Co-Chair and Chief of Internal Medicine at Helen Hayes Hospital, West Haverstraw, NY. "Globally we have an aging female population that wants to maintain independence and vitality. We can help by finding the key to improving diagnosis and treatment of this debilitating disease."

GLOW will monitor tens of thousands of older women who have visited a primary care physician in the past two years. Since patient recruitment for GLOW is not linked to osteoporosis diagnosis and does not alter physician practice, the study provides a good representation of "typical" older women and the bone health care they receive in the real world. Women are participating from 17 cities in 10 countries on 3 continents.

"We want to understand regional differences in physician and patient behavior and how that impacts patient outcomes," said Professor Pierre Delmas, GLOW Executive Committee Co-Chair and Professor of Medicine and Rheumatology, Universite Claude Bernard, Lyon, France. "Hopefully, armed with that knowledge we will be able to recommend best practices and improve the management of osteoporosis worldwide."

GLOW is being conducted by The Center for Outcomes Research (COR), University of Massachusetts Medical School (UMMS), with the support of an unrestricted research grant from The Alliance for Better Bone Health. The Alliance for Better Bone Health is a collaboration between sanofi-aventis and Procter & Gamble Pharmaceuticals.

"We are grateful for the commitment of the sponsors and scientific advisors to the GLOW project. We anticipate that these data will provide important information to improve the quality of lives of women at risk for osteoporotic fractures," said Dr. Fred Anderson, Director of the Center for Outcomes Research and research professor of surgery and medicine at UMMS. "This pioneering initiative will be the first comprehensive multi-national look into the relationship between risk factors, patient outcomes and treatment patterns for osteoporosis."

Milestone data from GLOW will be communicated on an ongoing basis at international medical conferences and through peer-reviewed publications. For more information on GLOW, please visit: http://www.outcomes.org/glow/

About GLOW

GLOW is a prospective, longitudinal, observational study of women over 55 years of age who visited a primary care physician during the two years prior to the study. Women were recruited through 700 primary care physicians in 17 cities in North America, Europe, and Australia. GLOW will gather information on osteoporosis risk factors, treatment approaches, patient behavior, and fracture outcomes with an annual patient survey over a 5 year period.
GLOW study sites are the following:

Lyon, France

Paris, France

Leuven, Belgium

Amsterdam, Netherlands

Barcelona, Spain

Essen, Germany

Verona, Italy

Southampton, UK

West Haverstraw, NY USA

Worcester, MA USA

Pittsburgh, PA USA

Seattle, WA USA

Cincinnati, OH USA

Los Angeles, CA USA

Birmingham, AL USA

Hamilton, Ontario Canada

Sydney, Australia

Notes to Editors

Spokespeople available for comment:

Dr. Robert Lindsay

Executive committee co-chair, GLOW

Chief of Internal Medicine at Helen Hayes Hospital, West Haverstraw, NY

Professor Pierre Delmas

Executive committee co-chair, GLOW Professor of medicine and rheumatology, Universite Claude Bernard, Lyon, France

About osteoporosis

Osteoporosis-related fragility fractures are an international public health problem responsible for increased mortality, functional impairment and added health care costs. Estimates are that between 40 and 50 percent of white women above the age of 50 in North America, Europe and Australia will incur an osteoporosis-related fracture in their lifetime. Although their rates are lower, non-white women and men are also susceptible. Because the likelihood of fragility fractures increases dramatically with age, fracture numbers are projected to rise as the population ages.

About the Center for Outcomes Research (COR)

COR is based at the University of Massachusetts, Worcester, MA, USA. The mission of COR is to collect and evaluate data that reflect real world practices and outcomes and to provide physicians with confidential reports that allow comparison of their practices to evidence based performance standards. For more information, please visit: http://www.outcomes.org


'/>"/>
SOURCE University of Massachusetts
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Reps. Smith and Doyle, Autism Society of America Push Landmark Legislation on World Autism Awareness Day
2. Landmark Pediatric Allergies in America Survey Uncovered Negative Impact of Allergy Symptoms on Children
3. Leukemia Survivor Reaches Landmark Settlement With TransUnion in ID Theft Case
4. Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark
5. Landmark WHO Report on Global Tobacco Epidemic Should Spur Urgent Action by Nations to Implement Proven Solutions
6. Landmark Articles Published by QualityMetric Scientists Report Improvements in Short Form Health Status Measures and Establish Criteria for Future Development
7. IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide
8. Hospital Launches Landmark Project in Emergency Medicine
9. Yale launches landmark VIRGO study of young women with heart disease
10. Safeway Inc. and the Prostate Cancer Foundation to Fund Landmark Prostate Cancer Research Collaboration
11. Landmark trial to evaluate cardioprotective properties of insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology: